October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

Clinical-grade Computational Pathology: Alea Iacta Est Filippo Fraggetta J Pathol Inform 2019, 10:38 (11 December 2019) [ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub] Whole-slide image...

American Cancer Society says advances in treating lung and skin cancers contributed to the 2.2% drop in cancer mortality By Brianna Abbott - WSJ The cancer death rate in the U.S. dropped 2.2% from 2016 to 2017, the largest single-year...

Partnership to leverage Illumina's extensive decentralised installed base with Roche's expertise in assay development and to provide broad access to clinical oncology next-generation sequencing Comprehensive genomic testing improves...

These twelve artificial intelligence innovations are expected to start impacting clinical care by the end of the decade. By Jennifer Bresnick of HeatlhITAnalytics.com There’s no question that artificial intelligence is moving...

REGISTER NOW Just like a recipe, every image analysis workflow is made up of steps. By solving one problem at a time, workflows become more manageable and get you to your result quicker. During this webinar, image analysis expert Dave Mason...

Series B investment to accelerate commercial efforts in the U.S., Europe, Brazil, Canada and to grow product portfolio NEW YORK--(BUSINESS WIRE) -- Paige, the leader in computational pathology transforming the diagnosis...

OR

platinum partners

gold partners

Silver Partners

Media Partners